Abstract | AIMS: METHODS: RESULTS:
Rivaroxaban was associated with a lower risk of the composite outcome of death, myocardial infarction, stroke, or systemic embolism (rate difference per 10,000 patient-years [RD]=-86.8 [95% CI -143.6 to -30.0]) and fatal or critical organ bleeding (-41.3 [-68 to -14.7]). However, rivaroxaban was associated with a higher risk of major bleeding other than fatal or critical organ bleeding (55.9 [14.7 to 97.2]). Method 1 showed no difference between treatments (-35.5 [-108.4 to 37.3]). Methods 2-4 favored treatment with rivaroxaban (2: -96.8 [-157.0 to -36.8]; 3: -65.2 [-112.3 to -17.8]; 4: -54.8 [-96.0 to -10.2]). CONCLUSIONS:
Rivaroxaban was associated with favorable NCB compared with warfarin. The NCB was attributable to lower rates of ischemic events and fatal or critical organ bleeding.
|
Authors | Adam S Barnett, Derek D Cyr, Shaun G Goodman, Bennett S Levitan, Zhong Yuan, Graeme J Hankey, Daniel E Singer, Richard C Becker, Günter Breithardt, Scott D Berkowitz, Jonathan L Halperin, Werner Hacke, Kenneth W Mahaffey, Christopher C Nessel, Keith A A Fox, Manesh R Patel, Jonathan P Piccini |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 257
Pg. 78-83
(04 15 2018)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 29506743
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2017 Elsevier B.V. All rights reserved. |
Chemical References |
- Anticoagulants
- Factor Xa Inhibitors
- Warfarin
- Rivaroxaban
|
Topics |
- Aged
- Anticoagulants
(administration & dosage, adverse effects)
- Atrial Fibrillation
(diagnosis, drug therapy, physiopathology)
- Double-Blind Method
- Factor Xa Inhibitors
(administration & dosage, adverse effects)
- Female
- Follow-Up Studies
- Hemorrhage
(chemically induced, diagnosis, physiopathology)
- Humans
- International Normalized Ratio
(methods)
- Internationality
- Male
- Retrospective Studies
- Rivaroxaban
(administration & dosage, adverse effects)
- Stroke
(diagnosis, physiopathology, prevention & control)
- Warfarin
(administration & dosage, adverse effects)
|